Topical bacterial lysates in the treatment of patients with infectious and inflammatory diseases of the ENT organs

Infectious and inflammatory diseases of the upper respiratory tract occupy one of the leading positions in the overall morbidity structure of the population worldwide. Among these diseases, the pharynx, nasal cavity and paranasal sinuses are most often affected. Against this background, the resistance of certain pathogens to etiotropic drugs is growing and the arsenal of pathogenetic therapies is insufficient, which creates the need to find alternative medicines. One of the possible alternative therapy options is a group of immunomodulatory drugs, among which bacterial lysates are the most popular. There is already sufficient evidence in the modern literature on the efficacy and safety of bacterial lysate preparations. Topical bacterial lysates have a stimulating effect on various links of specific and nonspecific immunity. They act directly in the focus of the disease, do not harm the body’s own microbiome, combine well with other medicines and can be used in patients of any age. Bacterial lysates are considered as an effective component of therapy of infectious and inflammatory diseases of the upper respiratory tract. They lead to the elimination of pathogenic pathogens, stimulate the body’s own defense mechanisms, and also contribute to the restoration of autoregulation of the local immune response. The use of bacterial lysate preparations leads to the activation of mucosal immunity and a decrease in the incidence of infectious diseases. Topical immunomodulators also have a preventive effect, preventing the occurrence of possible respiratory infections and improving the quality of life of patients. The use of drugs bacterial lysates show good clinical results, they contribute to improving the effectiveness of therapy and preventive measures.